RespireRx Pharmaceuticals — Investor Presentation (March 2020)
16 slides from RespireRx Pharmaceuticals's investor presentation, Mar 9, 2020
Slide 1: Newco: A New Pharmaceutical Cannabinoid Company
RespireRx Pharmaceuticals Inc March 9, 2020 OTC QB: RSPI Newco: A New Pharmaceutical Cannabinoid Company
Slide 2: Forward Looking Statements
Forward Looking Statements RespireRx Pharmaceuticals Inc This progress presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Company intends that such forward-looking sta
Slide 3: Creation of Newco
Creation of Newco« RespireRx Pharmaceuticals Inc The commercialization of pharmaceutical cannabinoids has opened the door to a potentially large, expanding pharmaceutical cannabinoid market opportunity. In order to capitalize on this opportunity, RespireRx is creating a new clinical-stage biopharmac
Slide 4: Foundations of Newco
Foundations of Newco~ RespireRx Pharmaceuticals Inc 1. Development of Pharmaceutical Cannabinoids - refers to the development of cannabinoids according to FDA and other foreign accepted regulatory pathways by which a company receives approval to market and sell a new drug. 2. Clinical Validation - t
Slide 5: 1. Pharmaceutical Cannabinoids
1. Pharmaceutical Cannabinoids Cannabinoids are pharmacologically active substances found in the marijuana plant The FDA has not recognized or approved the marijuana plant as medicine and it is not legal to sell products that contain cannabinoids as drugs or dietary supplements, other than those alr
Slide 6: 1. Pharmaceutical Cannabinoids
1. Pharmaceutical Cannabinoids DH RespireRx Pharmaceuticals Inc Marinol ® (dronabinol) - synthetically manufactured THC formulated as a soft gel capsule was the first pharmaceutical cannabinoid approved by the FDA in 1986. Sold as a Schedule 3 drug for the treatment of HIV/AIDS related anorexia and
Slide 7: 2. Dronabinol for Obstructive Sleep Apnea
2. Dronabinol for Obstructive Sleep Apnea BR RespireRx Sleep Apnea * Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep * Three types: Obstructive, Central & Mixed The Sleep Apnea Market is Large ¢ Approximately 30 million U.S. adults suffe
Slide 8: Dronabinol: Two Successful Phase 2 Studies
Dronabinol: Two Successful Phase 2 Studies BR Two Phase 2 Clinical Trials Demonstrated a Statistically Significant, Dose Related Improvement in the Apnea Hypopnea Index (AHI) the “Gold Standard” Primary Endpoint needed for FDA Approval Apnea-Hypopnia Index (AHI) 40 Placebo 2.5 mg p=.02 10 mg p=.001
Slide 9: 3. Proprietary Intellectual Property
3. Proprietary Intellectual Property RN RespireRx Patents in the United States, Germany and the United Kingdom claiming a method of treating sleep apnea by administering cannabinoids, including dronabinol, when administered either alone or in combinations.
Slide 10: Present Dronabinol Gel-cap Formulations
Present Dronabinol Gel-cap Formulations WD RespireRx ¢ Poor and erratic absorption, with some patients achieving very high levels and others achieving very low levels. ¢ Rapid and extensive first-pass liver metabolism, resulting in low blood levels and a relatively short half-life (approximately 3 -
Slide 11: New Formulations Based on Clinical Data
AAHI versus Baseline New Formulations Based on Clinical Data Change in AHI in the 15 4 hours vs. the 2" 4 hours of the night n= 17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours mist Half = 2nd Half DN RespireRx Pharmaceuticals Inc Low-dose dronabinol is as effective as the high dose in
Slide 12: 3. Proprietary Intellectual Property
3. Proprietary Intellectual Property DH RespireRx ¢ US and foreign pending patents claim cannabinoid compositions and methods for treating cannabinoid-sensitive disorders, with specific low dosage strengths and controlled release formulations for attaining a therapeutic window of cannabinoid blood l
Slide 13: 4. Regulatory Strategy
4. Regulatory Strategy GAS) Respi reRx e Under the 505(b)(2) NDA regulatory pathway in the US, the requirements for FDA approval are substantially reduced. « Using the 505(b)(2) regulatory approach, existing labelling information of an approved Listed Drug (Marinol ®) and/or published literature may
Slide 14: 5. NEWCO Business Plan in Place
5. NEWCO Business Plan in Place d)RespireRx Pharmaceuticals Inc 1. New, highly experienced senior executive identified as CEO 2. Regulatory plan developed with Camargo Pharmaceutical Services, pre-eminent advisory firm for 505(b)(2) filings, greatly reducing the requirements for FDA approval 3. Join
Slide 15: New Product Development Steps
New Product Development Steps RN RespireRx Pharmaceuticals Inc Upon completion of additional financing: 1. Finalize discussions and enter into development agreement with formulation company for new proprietary formulation 2. Acquire preclinical PK data on new formulation and have pre-IND meeting wit
Slide 16: Contact
RespireRx Pharmaceuticals Inc OTE QB: RSPI Contact: Jeff Margolis, CFO [email protected] 917-834-7206
RespireRx Pharmaceuticals — Investor Presentation (March 2020) on 6ix